Valiant Organics to acquire 34.26% stake in Valiant Laboratories via off-market deal
Valiant Organics Limited will acquire 1,86,07,531 equity shares, representing 34.26% of Valiant Laboratories Limited, from Dhanvallabh Ventures LLP. This off-market transaction is part of VOL's restructuring exercise. The acquisition price will not exceed 25% of the 60-day VWAP of ₹62.71.
The acquisition of over 34% of the share capital represents a substantial change in the ownership structure of Valiant Laboratories Limited, indicating a high impact on the company's corporate governance and strategic direction.
The acquisition by Valiant Organics Limited of a significant stake in Valiant Laboratories Limited is a strategic move that is likely to be viewed positively as part of a restructuring exercise.
Valiant Organics Limited (VOL) has announced its intention to acquire 1,86,07,531 equity shares of Valiant Laboratories Limited (VLL) from Dhanvallabh Ventures LLP (DVLLP) through an off-market transaction. This acquisition represents 34.26% of VLL's total share capital.
The proposed acquisition is part of a restructuring exercise being undertaken by VOL. The acquirer, VOL, is a member of the promoter group of the target company, VLL. The acquisition will be executed under Regulation 10(1)(a)(iii) read with Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, exempting VOL from making an open offer.
The shares will be acquired at a price not exceeding the limits provided in the SEBI SAST Regulations. The volume-weighted average market price for the 60 trading days preceding the notice date was ₹62.71 per equity share, and the acquisition price will not be higher by more than 25% of this computed price. The transaction is subject to the receipt of requisite approvals and is expected to occur any time after 4 working days from the date of the intimation (May 19, 2026).
Post-transaction, Dhanvallabh Ventures LLP's shareholding in VLL will reduce from 46.84% (2,54,37,500 shares) to 12.58% (68,29,969 shares), while Valiant Organics Limited will hold 34.26% (1,86,07,531 shares) of VLL's total share capital.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.